Pregnancy and breastfeeding outcome in patients with atopic dermatitis treated with dupilumab: the clinical experience of three centers. - Suppr | 超能文献

Pregnancy and breastfeeding outcome in patients with atopic dermatitis treated with dupilumab: the clinical experience of three centers.

作者信息

Xará Joana, Farinha Pedro, Lé Ana M, Duarte Bruno, Torres Tiago, Gonçalo Margarida

机构信息

Department of Dermatology, Coimbra Local Health Unit, Faculty of Medicine, University Hospital, Coimbra, Portugal.

Department of Dermatology, Centro Hospitalar Universitário de Lisboa Central EPE, Lisbon, Portugal.

出版信息

Int J Dermatol. 2024 Nov;63(11):e335-e337. doi: 10.1111/ijd.17410. Epub 2024 Aug 1.

DOI:10.1111/ijd.17410

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Pregnancy and breastfeeding outcome in patients with atopic dermatitis treated with dupilumab: the clinical experience of three centers.

Int J Dermatol. 2024 Nov;63(11):e335-e337. doi: 10.1111/ijd.17410. Epub 2024 Aug 1.

2

No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab.在长达 4 年的时间里，接受度普利尤单抗治疗的中重度特应性皮炎成人患者的总体感染风险没有增加。

Adv Ther. 2023 Jan;40(1):367-380. doi: 10.1007/s12325-022-02322-y. Epub 2022 Nov 1.

3

Evaluation of adult patients with atopic dermatitis treated with dupilumab: A single-center real-life experience.成人特应性皮炎患者接受度普利尤单抗治疗的评估：一项单中心真实世界经验。

J Cosmet Dermatol. 2022 Oct;21(10):4781-4787. doi: 10.1111/jocd.14785. Epub 2022 Jan 30.

4

A Single-Center Experience with Dupilumab for Atopic or Psoriasiform Dermatitis in Patients with Inflammatory Bowel Disease.单中心应用度普利尤单抗治疗炎症性肠病伴特应性皮炎或银屑病样皮炎患者的经验。

Dig Dis Sci. 2023 Apr;68(4):1121-1124. doi: 10.1007/s10620-022-07684-5. Epub 2022 Sep 5.

5

Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).度普利尤单抗治疗青少年中重度特应性皮炎的长期疗效和安全性：III 期开放标签扩展试验（LIBERTY AD PED-OLE）的第 52 周结果。

Am J Clin Dermatol. 2022 May;23(3):365-383. doi: 10.1007/s40257-022-00683-2. Epub 2022 May 14.

6

Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis.度普利尤单抗治疗可使成人特应性皮炎患者的症状和生活质量在两年内持续改善。

Dermatol Ther (Heidelb). 2021 Dec;11(6):2147-2157. doi: 10.1007/s13555-021-00630-9. Epub 2021 Oct 29.

7

Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.青少年特应性皮炎或哮喘患者接受度普利尤单抗临床试验中的结膜炎。

Am J Clin Dermatol. 2021 Jan;22(1):101-115. doi: 10.1007/s40257-020-00577-1.

8

Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis.一项为期 16 周的随机 III 期研究：度普利尤单抗对 6 个月至 5 岁中重度特应性皮炎儿童的实验室安全性。

Paediatr Drugs. 2023 Jan;25(1):67-77. doi: 10.1007/s40272-022-00553-8. Epub 2022 Dec 19.

9

The use of dupilumab in severe atopic dermatitis during pregnancy: a case report.妊娠期间重度特应性皮炎使用度普利尤单抗：一例病例报告。

Allergy Asthma Clin Immunol. 2022 Feb 3;18(1):9. doi: 10.1186/s13223-022-00650-w.

10

Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.真实世界中成人特应性皮炎患者接受度普利尤单抗治疗的经验：患者病历的回顾性分析。

Int J Dermatol. 2020 Feb;59(2):253-256. doi: 10.1111/ijd.14573. Epub 2019 Jul 8.

引用本文的文献

1

Dupilumab shows no elevated risk for maternal adverse pregnancy outcomes: A propensity-matched cohort study.度普利尤单抗未显示出孕产妇不良妊娠结局风险升高：一项倾向匹配队列研究。

J Eur Acad Dermatol Venereol. 2025 Sep;39(9):1576-1587. doi: 10.1111/jdv.20670. Epub 2025 Apr 2.